Daymark Wealth Partners LLC Purchases 431 Shares of Humana Inc. (NYSE:HUM)

Daymark Wealth Partners LLC boosted its position in shares of Humana Inc. (NYSE:HUM) by 41.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,466 shares of the insurance provider’s stock after acquiring an additional 431 shares during the period. Daymark Wealth Partners LLC’s holdings in Humana were worth $548,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. increased its position in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the last quarter. Hantz Financial Services Inc. purchased a new stake in shares of Humana in the second quarter worth approximately $35,000. Family Firm Inc. bought a new stake in shares of Humana during the second quarter worth $37,000. Hollencrest Capital Management purchased a new stake in Humana in the 2nd quarter valued at about $40,000. Finally, Riverview Trust Co purchased a new stake in shares of Humana in the 2nd quarter worth $44,000. Institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on HUM. Morgan Stanley assumed coverage on Humana in a research report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target for the company. Truist Financial raised their price target on shares of Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research report on Monday, July 15th. Royal Bank of Canada increased their target price on Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. Finally, TD Cowen raised their price target on shares of Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Thirteen equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Humana currently has an average rating of “Hold” and an average target price of $398.70.

Humana Trading Up 2.1 %

HUM stock opened at $319.52 on Friday. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $530.54. The business has a fifty day simple moving average of $351.30 and a 200-day simple moving average of $344.65. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a market cap of $38.50 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the company posted $8.94 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. On average, equities research analysts expect that Humana Inc. will post 16.01 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a yield of 1.11%. Humana’s payout ratio is currently 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.